Health Care & Life Sciences » Pharmaceuticals | Auris Medical Holding AG

Auris Medical Holding AG | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
80.80
96.40
99.10
124.70
223.80
Gross Income
-
80.80
96.40
99.10
124.70
223.80
SG&A Expense
15,679.80
23,212.40
31,947.40
30,584.80
24,607.30
10,939.30
EBIT
15,765.70
23,345.90
32,068.10
30,678.30
24,750.80
11,193
Unusual Expense
-
898.40
-
295.40
2,382.90
1,379.50
Non Operating Income/Expense
112.50
4,382.90
1,188.20
101.60
837.80
674.40
Interest Expense
56.80
61.00
8.30
841.00
1,666.60
1,093.50
Pretax Income
15,855.10
19,865.40
30,850.20
31,257.00
24,817.80
11,581.30
Income Tax
329.80
-
-
133.00
18.10
165.70
Consolidated Net Income
16,184.90
19,865.40
30,850.20
31,123.90
24,799.80
11,747.10
Net Income
16,184.90
19,865.40
30,850.20
31,123.90
24,799.80
11,747.10
Net Income After Extraordinaries
16,184.90
19,865.40
30,850.20
31,123.90
24,799.80
11,747.10
Net Income Available to Common
16,184.90
19,865.40
30,850.20
31,123.90
24,799.80
11,747.10
EPS (Basic)
5.72
7.21
9.55
9.03
5.69
14.78
Basic Shares Outstanding
2,824.10
2,769.20
3,229.90
3,432.90
4,374.20
795
EPS (Diluted)
5.73
7.17
9.55
9.07
5.67
14.78
Diluted Shares Outstanding
2,824.10
2,769.20
3,229.90
3,432.90
4,374.20
795
EBITDA
15,725.20
23,265.10
31,971.80
30,579.30
24,626.00
10,969.20
Other Operating Expense
45.40
52.70
24.40
5.50
18.70
29.80
Non-Operating Interest Income
79.90
57.00
38.00
68.60
54.40
-

About Auris Medical Holding

View Profile
Address
Clarendon House
Hamilton HC HM 11
Bermuda
Employees -
Website http://www.aurismedical.com
Updated 07/08/2019
Auris Medical Holding AG engages in the provision of biopharmaceutical business. It focuses on the development of novel products for the treatment of inner ear disorders. It includes tinnitus, haring loss, and meniere's disease.